Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis.

被引：0

作者：

Lee, HG ^{[1
]}

Lee, JJ ^{[1
]}

Jung, KH ^{[1
]}

Kwon, Y ^{[1
]}

Shin, EH ^{[1
]}

Chung, KW ^{[1
]}

Shin, KH ^{[1
]}

Kim, EA ^{[1
]}

Lee, ES ^{[1
]}

Ro, J ^{[1
]}

机构：

[1] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

607

引用

页码：29S / 29S

页数：1

共 50 条

[1] Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC)
Ahn, Joong-Bae
Oh, Jung-Hye
Kwon, Youngmee
Chung, Ki-Wook
Kang, Han-Sung
Shin, Kyung Hwan
Kim, Eun-A
Lee, Eun Sook
Ro, Jungsil
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 57 - 57
[2] Docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC): interim analysis findings from a phase III randomised trial
不详
[J]. BREAST, 2005, 14 : S40 - S40
[3] Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC).
Lee, KS
Lee, ES
Kwon, YM
Nam, BH
Kwon, HS
Chung, KW
Kang, HS
Kim, EA
Kim, SW
Ro, J
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S224 - S224
[4] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
Lee, Keun Seok
Ro, Jungsil
Nam, Byung-Ho
Lee, Eun Sook
Kwon, Youngmee
Kwon, Hye Soo
Chung, Ki Wook
Kang, Han Sung
Kim, Eun A.
Kim, Seok Won
Shin, Kyung Hwan
Kim, Seok-Ki
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 481 - 489
[5] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
Keun Seok Lee
Jungsil Ro
Byung-Ho Nam
Eun Sook Lee
Youngmee Kwon
Hye Soo Kwon
Ki Wook Chung
Han Sung Kang
Eun A Kim
Seok Won Kim
Kyung Hwan Shin
Seok-Ki Kim
[J]. Breast Cancer Research and Treatment, 2008, 109 : 481 - 489
[6] Phase-III trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide for primary breast cancer
Mross, Klaus
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (04) : 253 - 254
[7] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial
Nabholtz, JM
Falkson, C
Campos, D
Szanto, J
Martin, M
Chan, S
Pienkowski, T
Zaluski, J
Pinter, T
Krzakowski, M
Vorobiof, D
Leonard, R
Kennedy, I
Azli, N
Murawsky, M
Riva, A
Pouillart, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 968 - 975
[8] Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer:: Phase III randomized GeparTrio trial
von Minckwitz, Gunter
Kuemmel, Sherko
Vogel, Petra
Hanusch, Claus
Eidtmann, Holger
Hilfrich, Joern
Gerber, Bernd
Huober, Jens
Costa, Serban Dan
Jackisch, Christian
Loibl, Sibylle
Mehta, Keyur
Kaufmann, Manfred
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (08) : 542 - 551
[9] Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
Feng, Yan-Ru
Zhu, Yuan
Liu, Lu-Ying
Wang, Wei-Hu
Wang, Shu-Lian
Song, Yong-Wen
Wang, Xin
Tang, Yuan
Liu, Yue-Ping
Ren, Hua
Fang, Hui
Zhang, Shi-Ping
Liu, Xin-Fan
Yu, Zi-Hao
Li, Ye-Xiong
Jin, Jing
[J]. ONCOTARGET, 2016, 7 (18) : 25576 - 25584
[10] Anemia in stage II and III breast cancer patients treated with doxorubicin and cyclophosphamide (AC).
Kirshner, J
Hatch, M
Hennessy, DD
Tannous, RE
Fridman, M
Gupta, S
[J]. BLOOD, 2002, 100 (11) : 498B - 499B

← 1 2 3 4 5 →